Search / Trial NCT00000685

A Study of Zidovudine in HIV-Infected Patients With Kidney Problems

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of June 14, 2024

Withdrawn

Keywords

Kidney Diseases Drug Evaluation Acquired Immunodeficiency Syndrome Zidovudine Renal Dialysis

Description

AZT is the only antiviral agent with demonstrated effectiveness in patients with severe HIV infection. Persons with HIV infection may have additional health problems, one of which is a diseased kidney due to infection of the kidney, or side effects of therapy. The benefits and risks of AZT in patients with diseased kidneys are unknown. It is hoped that this study will allow further understanding of the metabolism and excretion of AZT in patients with kidney disease. AZT pharmacokinetics will be studied in patients with mild, moderate, and severe renal disorders. Patients receive AZT by mou...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Symptomatic therapy such as analgesics, antihistamines, antiemetics, antidiarrheal agents, or other supportive therapy.
  • Aerosolized pentamidine.
  • Discouraged:
  • - Sucralfate or antacids. However if these medications are essential for the patient's management, they should not be given within 8 hours before or 2 hours after the scheduled pharmacokinetic study.
  • -
  • Concurrent Treatment:
  • Allowed:
  • Blood transfusions.
  • Patients must have HIV infection with renal insufficiency and acceptable hepatic and hematologic function. They must have been on dialysis treatment for at least 3 months.
  • Prior Medication:
  • Allowed:
  • Cytotoxic chemotherapy for local mucocutaneous lesions.
  • Aerosolized pentamidine.
  • Exclusion Criteria
  • Concurrent Medication:
  • Excluded:
  • Ongoing therapy for opportunistic infections, including systemic maintenance therapy which cannot be discontinued for the duration of the study, such as amphotericin B or ganciclovir.
  • H-2 blockers.
  • Zidovudine (AZT).
  • Other antiretroviral agents or other experimental therapy.
  • Discouraged:
  • - Sucralfate or antacids. However, if these medications are essential for the patient's management, they should not be given within 8 hours before or 2 hours after the scheduled pharmacokinetic study.
  • -
  • Patients will be excluded from the study for the following reasons:
  • Presence of active opportunistic infections.
  • Severe malabsorption syndrome (persistent diarrhea greater than 4 weeks duration with = or > 4 loose stools per day accompanied by = or > 10 percent unintentional weight loss.
  • Acute illness, febrile or unstable, 48 hours prior to the first pharmacokinetic study.
  • Known sensitivity to zidovudine or thymidine-type agents.
  • Diabetes mellitus requiring treatment.
  • Prior Medication:
  • Excluded:
  • - Treatment for diabetes mellitus.
  • Excluded within 72 hours of study entry:
  • H-2 blockers.
  • Zidovudine (AZT).
  • Excluded within 2 weeks of study entry:
  • Other antiretroviral agents or other experimental therapy.
  • Rifampin or rifampin derivatives.
  • Probenecid.
  • Dilantin.
  • Methadone.
  • Oral contraceptives.
  • Barbiturates.
  • Significant hepatotoxic agents or valproic acid.
  • TMP / SMX.
  • Dapsone.
  • Fansidar.
  • Excluded within 30 days of study entry:
  • - Cytotoxic chemotherapy.
  • Prior Treatment:
  • Excluded within 30 days of study entry:
  • Radiation therapy for local mucocutaneous lesions.
  • Risk Behavior:
  • Active drug or alcohol use which might interfere with the study objectives.
  • Note: Alcohol consumption is prohibited 48 hours prior to the first pharmacokinetic study and during the study. Tobacco smoking is not excluded although tobacco use will be quantified.
  • Patients may not have any of the following diseases or symptoms:
  • Presence of active opportunistic infections.
  • Severe malabsorption syndrome (persistent diarrhea greater than 4 weeks duration with = or > 4 loose stools per day accompanied by = or > 10 percent unintentional weight loss.
  • Acute illness, febrile or unstable, 48 hours prior to the first pharmacokinetic study.
  • Diabetes mellitus.

Attachments

readout_NCT00000685_2024-06-14.pdf

4.5 MB

NCT00000685_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Seattle, Washington, United States

Chapel Hill, North Carolina, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0